Figure 3.

IXE dose* observed in real‐world setting versus recommended (based on prescribing information for United States Food and Drug Administration [FDA]–approved dose). For patients with comorbid psoriasis (PsO), the dose was measured during an induction period of 12 weeks and then during maintenance starting at Week 14 and continuing until discontinuation or the end of the 12‐month follow‐up period. The recommended dose based on prescribing information for the FDA‐approved dose was defined as 160 mg at Week 0 followed by 80 mg at Weeks 2,4,5,8,10, and 12 (equivalent to a dose of 91 mg biweekly over the entire induction period).